Author:
G. Prajapati Bhupendra, ,B. Prajapati Bhavesh,M. Rathod Sapna
Abstract
A simple, precise, reproducible and sensitive RP HPLC method was developed and validated for the quantification of exemestane (EXM) in nanoemulsion. The method was developed using Phenomenex C18 column (250 mm × 4.6 mm i.d., 5 µm) and acetonitrile: methanol (40:60 V/V) was used as mobile phase. The flow rate was maintained at 1.0 mL min-1. The analyte was monitored at 249 nm. The analyte shows linear response in the range of 0.5–5 µg mL-1. The developed method was validated as per ICH guidelines for accuracy, precision, limit of detection, limit of quantitation and robustness. The data for precision studies revealed that the method is precise, as % RSD is less than 2. The standard addition method was used for the accuracy study and the method showed 100.3 ± 0.47 % recovery for the drug. The proposed method can be successfully applied to the dosage form.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference23 articles.
1. 1. Buzdar A.U., Robertson J.F., Eiermann W. and Nabholtz J. M.: An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer, 2002, 95(9) 2006-2016.
2. 2. Theobald A. J.: Management of advanced breast cancer with endocrine therapy: the role of the primary healthcare team, Int. J. Clin. Pract., 2000, 54(10) 665-669.
3. 3. Di Salle E., Ornati G., Giudici D., Lassus M., Evans T. R. and R. C. Coombes.: Exemestane (FCE 24304), a new steroidal aromatase inhibitor, J. Steroid Biochem. Mol. Biol., 1992, 43(1-3) 137-143.
4. 4. Pagani O., Regan M. M., Walley B.A., Fleming G. F. et al.: International Breast Cancer Study Group 2014. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer, N. Engl. J. Med., 2014, 371(2) 107-118.
5. 5. Wang R., Billone P. S. and Mullett W. M.: Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trial, J. Nanomater., 2013, Article ID 629681 1-12.